259 related articles for article (PubMed ID: 20082699)
1. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
Patel SN; Melano R; McGeer A; Green K; Low DE
Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
3. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
5. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
6. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
7. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
8. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
9. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
[TBL] [Abstract][Full Text] [Related]
10. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
11. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
12. Co-existence of plasmid-mediated quinolone resistance determinants and mutations in gyrA and parC among fluoroquinolone-resistant clinical Enterobacteriaceae isolated in a tertiary hospital in Warsaw, Poland.
Piekarska K; Wołkowicz T; Zacharczuk K; Rzeczkowska M; Chróst A; Bareja E; Olak M; Gierczyński R
Int J Antimicrob Agents; 2015 Mar; 45(3):238-43. PubMed ID: 25468717
[TBL] [Abstract][Full Text] [Related]
13. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
14. gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya.
Kivata MW; Mbuchi M; Eyase FL; Bulimo WD; Kyanya CK; Oundo V; Muriithi SW; Andagalu B; Mbinda WM; Soge OO; McClelland RS; Sang W; Mancuso JD
BMC Microbiol; 2019 Apr; 19(1):76. PubMed ID: 30961546
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
16. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
17. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
Ip M; Chau SS; Chi F; Qi A; Lai RW
J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
[TBL] [Abstract][Full Text] [Related]
18. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
Stewart BA; Johnson AP; Woodford N
J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
